Donald Kennedy is President Emeritus and Bing Professor of Environmental Science and Policy, Emeritus at Stanford University. He is also a Senior Fellow of the Freeman-Spogli Institute for International Studies and the Wood Institute for the Environment, and is a member of the Food Security and Environment Program in both Institutes. Dr. Kennedy was editor-in-chief of Science (2000-2008) and also served as Commissioner of the US Food and Drug Administration during the Carter administration. Dr. Kennedy is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. He served on the National Commission for Public Service and the Carnegie Commission on Science, Technology and Government, and is a founding director of the Health Effects Institute. He currently serves as a director of the Carnegie Endowment for International Peace, and as co-chair of the National Academies’ Project on Science, Technology and Law. Dr. Kennedy received A.B. and Ph.D. degrees in biology from Harvard University.

Lee Hartwell has been president and director of the Fred Hutchinson Cancer Research Center since 1997. Dr. Hartwell is the recipient of many national and international scientific awards, including the 2001 Nobel Prize in Physiology or Medicine for his work in yeast genetics. Other honors include the Albert Lasker Basic Medical Research Award, the Gairdner Foundation International Award and the Alfred P. Sloan Award in cancer research. Dr. Hartwell became professor of genetics at the University of Washington in 1973, where he joined the faculty in 1968. He was an assistant professor at the University of California, Irvine from 1965 to 1968. Dr. Hartwell engaged in postdoctoral work at the Salk Institute for Biological Studies from 1964 through 1965 with Dr. Renato Dulbecco. He is also a member of the National Academy of Sciences. Dr. Hartwell holds a B.S. degree from the California Institute of Technology and a Ph.D. Degree from the Massachusetts Institute of Technology under the mentorship of Dr. Boris Magasanik.

David Nathan is President Emeritus of Dana-Farber Cancer Institute, which provides patient care in addition to conducting research. He was president of DFCI from 1995 to 2000. Dr. Nathan chaired the Department of Pediatrics and served as physician-in-chief of Children’s Hospital in Boston from 1985 to 1995. He was chief of hematology and oncology at CHB and DFCI after serving as chief of hematology at CHB between 1967 and 1984. Dr. Nathan was senior resident in medicine at the then Peter Bent Brigham Hospital and clinical associate at the National Cancer Institute from 1959 to 1966. His textbook, titled Hematology of Infancy and Childhood, is the leading text in the field. He is the author of two popular books: Genes, Blood and Courage and The Cancer Treatment Revolution: How Smart Drugs and Other New Therapies Are Renewing Our Hope and Changing the Face of Medicine. Dr. Nathan is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Pediatric Society, the Institute of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. He is the recipient of numerous awards, including the National Medal of Science, the Stratton medal of the American Society of Hematology, the Walker Prize of the Boston Museum of Science, the John Howland Medal of the American Pediatric Society, and the George M. Kober Medal of the Association of American Physicians. He is one of only three physicians to receive both the Howland and Kober medals.

John Curd has been the President and Chief Medical Officer at Threshold Pharmaceuticals since 2007. He had joined Threshold Pharmaceuticals as a member of the management team to lead the clinical development of product development candidates including Threshold's hypoxia activated prodrug, TH-302. Prior to Threshold Pharmaceuticals, Dr. Curd was President and Chief Medical Officer at Novacea, Inc. since 2001. He had served in senior roles at Maxygen and VaxGen, Inc. from June 1999 to December 2001, and Vice President of Clinical Development at Genentech, Inc. from December 1991 to June 1999. While at Genentech, he directed the clinical development of Herceptin®, Rituxan®, Xolair®, and Raptiva®. From 1978 to 1991, Dr. Curd served in various positions including President of the Medical Staff at Scripps Clinical and Research Foundation in La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.